Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.17 -0.01 (-0.24%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
One biotech in particular that investors should be watching the cash burn rate of very closely is Arena Pharmaceuticals (NASDAQ: ARNA ) . With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond ...
Related articles »  
Arena Pharmaceuticals, Inc. Earnings: Looking for More
Most biotech investor would be happy with 30% quarter-over-quarter prescription growth in a market that didn't grow much. But for Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq, the growth is coming off such a small base that it's hard to get too excited.
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows  Zacks.com
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 ...  MarketWatch
Related articles »  
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and VIVUS's (NASDAQ: VVUS ) Qsymia reported a combined 283,000 prescriptions ...
Arena And Vivus Investors Need To Watch Orexigen  Seeking Alpha (registration)
Related articles »  
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals - A Biotech Value Investment  Seeking Alpha (registration)
Related articles »  
Arena Pharmaceuticals, Inc., Loews Corporation, and Sysco Corporation ...
As Capitol Hill keeps its eyes closely trained on November elections, Wall Street's attention is elsewhere as earnings season continues this week.
Related articles »  
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks.
Why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Rising?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) surged as much as 6.6%. It was a welcome reprieve for Arena shareholders, who had seen the stock lose 25% of its value this year before today's gains.
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?  Zacks.com
Geron Corp (NASDAQ:GERN) Skyrockets on Unusual Volume - Arena ...  StreetWise Report
Related articles »  
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Arena Pharmaceuticals (NASDAQ: ARNA ) held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline.
Belviq And Phentermine Study Awes Some Investors - Should It? (ARNA)  Seeking Alpha (registration)
Related articles »  
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
Orexigen's Contrave Approved by FDA  NBC 7 San Diego
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And ...  Bidness ETC
Related articles »  
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5%
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
Related articles »